Dawn Lee

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 20

Top Topics

Decision Making

Smoking Cessation

Advanced Non Small Cell Lung Cancer

Top Venues

PharmacoEconomics - open

Advances in therapy

Journal of medical economics

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Colin Burke, Catriona Crossan, Emma Tyas, Matthew Hemstock, Dawn Lee, Sally Bowditch
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales. PharmacoEconomics - open (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open (2024)
Rose J Hart, Fareen Hassan, Sarah Alulis, Karl W Patterson, Jennifer Norma Barthelmes, Jennifer H Boer, Dawn Lee
Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes. Advances in therapy 41 (5) (2024)
Rose J Hart, Fareen Hassan, Sarah Alulis, Karl W Patterson, Jennifer Norma Barthelmes, Jennifer H Boer, Dawn Lee
Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes. Advances in therapy (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open 8 (5) (2024)
Rose J Hart, Fareen Hassan, Sarah Alulis, Karl W Patterson, Jennifer Norma Barthelmes, Jennifer H Boer, Dawn Lee
Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes. Advances in therapy 41 (5) (2024)
Colin Burke, Catriona Crossan, Emma Tyas, Matthew Hemstock, Dawn Lee, Sally Bowditch
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales. PharmacoEconomics - open 8 (4) (2024)
Dawn Lee, Darren Burns, Ed Wilson
Correction: NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open (2024)
Dawn Lee, Darren Burns, Ed Wilson
Correction: NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open 8 (5) (2024)
Colin Burke, Catriona Crossan, Emma Tyas, Matthew Hemstock, Dawn Lee, Sally Bowditch
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales. PharmacoEconomics - open 8 (4) (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open (2024)
Rose J Hart, Fareen Hassan, Sarah Alulis, Karl W Patterson, Jennifer Norma Barthelmes, Jennifer H Boer, Dawn Lee
Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes. Advances in therapy 41 (5) (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open 8 (5) (2024)
Colin Burke, Catriona Crossan, Emma Tyas, Matthew Hemstock, Dawn Lee, Sally Bowditch
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales. PharmacoEconomics - open 8 (4) (2024)
Dawn Lee, Darren Burns, Ed Wilson
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - open (2024)
Raquel Aguiar-Ibáñez, Chloë Hardern, Frank van Hees, Dawn Lee, Anubhav Patel, Nitika Chhabra, Gargi Baluni, Mayur M Amonkar, Yizhen Lai, Ruifeng Xu, Rachid Massaad, David Fogelman
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Journal of medical economics 25 (1) (2022)
Dawn Lee, Grant McCarthy, Omar Saeed, Rachel Allen, Kinga Malottki, Fleur Chandler
The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products. PharmacoEconomics - open (2022)
Tim S Grant, Darren Burns, Christopher Kiff, Dawn Lee
A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity. PharmacoEconomics 38 (4) (2021)
Ash Bullement, Yang Meng, Miranda Cooper, Dawn Lee, Tara Louise Harding, Chris O'Regan, Raquel Aguiar-Ibanez
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available? Journal of medical economics 22 (3) (2018)